Allegro Ophthalmics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $30.2M

  • Investors
  • 4

Allegro Ophthalmics General Information

Description

Operator of an ophthalmic biopharmaceutical company intended to redefine the retina space with integrin inhibition therapy. The company's lead investigational drug is a broad-spectrum integrin inhibitor, that downregulates oxidative stress upstream, at its source and simultaneously affects all four pathways of oxidative stress that contribute to retinal diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration, enabling ophthalmologists to treat ocular diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 31473 Rancho Viejo Road
  • Suite 204
  • San Juan Capistrano, CA 92675
  • United States
+1 (949)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 31473 Rancho Viejo Road
  • Suite 204
  • San Juan Capistrano, CA 92675
  • United States
+1 (949)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allegro Ophthalmics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 12-Oct-2021 $30.2M Completed Clinical Trials - Phase 2
6. Accelerator/Incubator 19-Sep-2017 Completed Clinical Trials - Phase 1
5. Later Stage VC 09-Jul-2017 Completed Clinical Trials - Phase 1
4. Grant 03-Feb-2015 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 26-Jan-2015 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 02-May-2013 $10M $11.5M Completed Clinical Trials - Phase 1
1. Angel (individual) 01-Apr-2012 $1.5M $1.5M Completed Clinical Trials - Phase 1
To view Allegro Ophthalmics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Allegro Ophthalmics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an ophthalmic biopharmaceutical company intended to redefine the retina space with integrin inhibition thera
Drug Discovery
San Juan Capistrano, CA
6 As of 2025

Stuart, FL
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allegro Ophthalmics Competitors (33)

One of Allegro Ophthalmics’s 33 competitors is Stuart Therapeutics, a Venture Capital-Backed company based in Stuart, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stuart Therapeutics Venture Capital-Backed Stuart, FL
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Kala Bio Formerly VC-backed Arlington, MA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 33 competitors. Get the full list »

Allegro Ophthalmics Patents

Allegro Ophthalmics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022529823-A Compositions and methods that can be used to treat dry eye Pending 22-Apr-2019
CA-3134362-A1 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019
EP-3958915-A1 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019
EP-3958915-A4 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019
US-20200345805-A1 Compositions and methods useable for treatment of dry eye Inactive 22-Apr-2019 A61K38/08
To view Allegro Ophthalmics’s complete patent history, request access »

Allegro Ophthalmics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allegro Ophthalmics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Octane (California) Accelerator/Incubator
The Leona M. and Harry B. Helmsley Charitable Trust Limited Partner
Bausch Health Companies Corporation Minority
Hanmi Pharm Corporation Minority
To view Allegro Ophthalmics’s complete investors history, request access »

Allegro Ophthalmics FAQs

  • When was Allegro Ophthalmics founded?

    Allegro Ophthalmics was founded in 2011.

  • Where is Allegro Ophthalmics headquartered?

    Allegro Ophthalmics is headquartered in San Juan Capistrano, CA.

  • What is the size of Allegro Ophthalmics?

    Allegro Ophthalmics has 6 total employees.

  • What industry is Allegro Ophthalmics in?

    Allegro Ophthalmics’s primary industry is Drug Discovery.

  • Is Allegro Ophthalmics a private or public company?

    Allegro Ophthalmics is a Private company.

  • What is Allegro Ophthalmics’s current revenue?

    The current revenue for Allegro Ophthalmics is .

  • How much funding has Allegro Ophthalmics raised over time?

    Allegro Ophthalmics has raised $72.7M.

  • Who are Allegro Ophthalmics’s investors?

    Octane (California), The Leona M. and Harry B. Helmsley Charitable Trust, Bausch Health Companies, and Hanmi Pharm have invested in Allegro Ophthalmics.

  • Who are Allegro Ophthalmics’s competitors?

    Stuart Therapeutics, Inovio Pharmaceuticals, Kala Bio, ONL Therapeutics, and Foventa Therapeutics are some of the 33 competitors of Allegro Ophthalmics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process